| Symbol | PHRX |
|---|---|
| Name | PHARMAGEN, INC. |
| Sector | UNDEFINED |
| Region | North America |
| Industry | - |
| Address | 20910 United States MD 9337 Fraser Avenue |
| Telephone | (204) 898-8160 |
| Fax | — |
| — | |
| Website | http://www.pharmageninc.com |
| Incorporation | US |
| Incorporated On | 2009 |
| Employees | — |
| Fiscal Year | 12/31 |
| Public Since | — |
| Exchanges | OTC |
| Auditor | M&K CPAS, PLLC; |
| Audit Status | AUDITED |
| Reporting Status | U.S. Reporting: SEC Reporting |
| CIK | 0001470915 |
| Description | With a multi-faceted approach, Pharmagen, Inc. is meeting the demands of the health provider market through dynamic, independent wholesale, compounding/admix, and innovative IT solutions. Nationally focused, we are a distributor of specialty drugs, compounding and admix pharmacy and producer of over-the-counter ("OTC") branded multivitamins to the healthcare provider market. The Food and Drug Administration continues to see an increasing number of shortages, especially those involving sterile injectable drugs. We currently function as a total solution provider to hospitals through sterile compounding/admix pharmacy and just-in-time source of supply of products that are hard-to-find due to drug manufacturers production shortages. Leveraging our understanding of drug shortages, our long term goal is to become an FDA approved manufacturer of habitually short supply, sterile pharmaceuticals. Through an industry changing, cGMP + process, utilizing single-use, modular systems, we intend to be the gold standard of sterile production in the United States. In addition to pharmaceuticals, we manufacture and distribute over-the-counter ("OTC") branded health supplements. Our innovative approach to OTC is to create suites of products that are designed to work in conjunction with prescription medications to alleviate side effects and/or prevent drug interactions. With an aging population, more Americans than ever are on prescription medications and dangerous drug interactions are a growing problem. We are currently analyzing several OTC products that would allow us to become a powerful OTC player in the multi-billon dollar health supplement market. Additional info from OTC: |
No news found.